全文获取类型
收费全文 | 1014篇 |
免费 | 75篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 58篇 |
妇产科学 | 9篇 |
基础医学 | 92篇 |
口腔科学 | 29篇 |
临床医学 | 169篇 |
内科学 | 218篇 |
皮肤病学 | 12篇 |
神经病学 | 31篇 |
特种医学 | 244篇 |
外科学 | 90篇 |
综合类 | 21篇 |
预防医学 | 35篇 |
眼科学 | 7篇 |
药学 | 43篇 |
中国医学 | 5篇 |
肿瘤学 | 30篇 |
出版年
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 10篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 23篇 |
2017年 | 11篇 |
2016年 | 18篇 |
2015年 | 21篇 |
2014年 | 26篇 |
2013年 | 23篇 |
2012年 | 18篇 |
2011年 | 17篇 |
2010年 | 36篇 |
2009年 | 55篇 |
2008年 | 28篇 |
2007年 | 11篇 |
2006年 | 18篇 |
2005年 | 6篇 |
2004年 | 8篇 |
2003年 | 20篇 |
2002年 | 16篇 |
2001年 | 18篇 |
2000年 | 11篇 |
1999年 | 15篇 |
1998年 | 51篇 |
1997年 | 52篇 |
1996年 | 65篇 |
1995年 | 49篇 |
1994年 | 44篇 |
1993年 | 47篇 |
1992年 | 18篇 |
1991年 | 10篇 |
1990年 | 22篇 |
1989年 | 43篇 |
1988年 | 38篇 |
1987年 | 32篇 |
1986年 | 35篇 |
1985年 | 25篇 |
1984年 | 24篇 |
1983年 | 14篇 |
1982年 | 22篇 |
1981年 | 16篇 |
1980年 | 9篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1971年 | 2篇 |
排序方式: 共有1096条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Sutada Lotinun Glenda L Evans James T Bronk Mark E Bolander Thomas J Wronski Erik L Ritman Russell T Turner 《Journal of bone and mineral research》2004,19(7):1165-1171
We examined the time course effects of continuous PTH on cortical bone and mechanical properties. PTH increased cortical bone turnover and induced intracortical porosity with no deleterious effect on bone strength. Withdrawal of PTH increased maximum torque to failure and stiffness with no change in energy absorbed. INTRODUCTION: The skeletal response of cortical bone to parathyroid hormone (PTH) is complex and species dependent. Intermittent administration of PTH to rats increases periosteal and endocortical bone formation but has no known effects on intracortical bone turnover. The effects of continuous PTH on cortical bone are not clearly established. MATERIALS AND METHODS: Eighty-four 6-month-old female Sprague-Dawley rats were divided into three control, six PTH, and two PTH withdrawal (WD) groups. They were subcutaneously implanted with osmotic pumps loaded with vehicle or 40 microg/kg BW/day human PTH(1-34) for 1, 3, 5, 7, 14, and 28 days. After 7 days, PTH was withdrawn from two groups of animals for 7 (7d-PTH/7d-WD) and 21 days (7d-PTH/21d-WD). Histomorphometry was performed on periosteal and endocortical surfaces of the tibial diaphysis in all groups. microCT of tibias and mechanical testing by torsion of femora were performed on 28d-PTH and 7d-PTH/21d-WD animals. RESULTS AND CONCLUSIONS: Continuous PTH increased periosteal and endocortical bone formation, endocortical osteoclast perimeter, and cortical porosity in a time-dependent manner, but did not change the mechanical properties of the femur, possibly because of addition of new bone onto periosteal and endocortical surfaces. Additionally, withdrawal of PTH restored normal cortical porosity and increased maximum torque to failure and stiffness. We conclude that continuous administration of PTH increased cortical porosity in rats without having a detrimental effect on bone mechanical properties. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.